A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study of MK0633 in Adult Patients With Chronic Asthma

Merck Sharp & Dohme LLC0 sites688 target enrollmentJanuary 2008

ConditionsAsthma

InterventionsMK0633

DrugsMK0633 Comparator: placebo

Overview

Phase: Phase 2
Intervention: MK0633
Conditions: Asthma
Sponsor: Merck Sharp & Dohme LLC
Enrollment: 688
Primary Endpoint: Pulmonary function test data measured over 6 weeks
Status: Terminated
Last Updated: 10 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

A clinical study to evaluate the efficacy and safety of MK0633 in adult patients with chronic asthma.

Registry

clinicaltrials.gov

Start Date

January 2008

End Date

June 2009

Last Updated

10 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Merck Sharp & Dohme LLC

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Documented clinical history of symptoms of chronic asthma, including dyspnea, wheezing, chest tightness, cough, and/or sputum production
•Males and females 18-70 years of age

Exclusion Criteria

•History of kidney or chronic liver disease
•Recent history of heart problems within the past 3 months
•Evidence of another clinically significant, active lung disorder such as bronchiectasis or COPD

Arms & Interventions

1

MK0633 10 mg

Intervention: MK0633

2

MK0633 50 mg

Intervention: MK0633

3

MK0633 100 mg

Intervention: MK0633

Outcomes

Primary Outcomes

Pulmonary function test data measured over 6 weeks

Time Frame: 6 weeks

Secondary Outcomes

Overall daytime and nighttime symptoms score, beta-agonist use, asthma exacerbations, asthma-specific quality of life questionnaire score, measured over 6 weeks(6 weeks)